Latest News
Cambridge, Massachusetts & Chicago, U.S.A. 19 December, 2023. Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, and EVERSANA®, a leading provider of commercialization services to the life science industry, today announced the commercial launch of JYLAMVO […]
Munich, Germany. 14 December 2023. Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for complement-mediated diseases, today announced the formation of its Medical Advisory Board which will help guide the development of […]
Munich, Germany. 9 November 2023. Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for complement-mediated diseases, today announced the enrolment of their first participant in the United States, an important milestone for […]
Leiden, The Netherlands. 2 November, 2023. Artica Therapeutics B.V. (Artica), a biotechnology company unlocking the power of medicines with insurmountable binding characteristics, today announced it has raised €12 million in Seed financing. The round was co-led […]
Galway, Ireland. 2 November 2023. Perfuze, a private medical device company dedicated to developing pioneering technology to treat acute ischemic stroke, announced commencement of enrollment in its pivotal MARRS (Millipede AspiRation for Revascularization in Stroke) clinical […]
October 31, 2023. Cambridge, Massachusetts and London. Shorla Oncology (‘Shorla’), a US-Ireland specialty pharmaceutical company, and Therakind Ltd (‘Therakind’), a UK-based speciality pharmaceutical company have entered into an agreement under which Shorla has agreed to acquire […]